McAlister Finlay A, Zarnke Kelly B, Campbell Norman R C, Feldman Ross D, Levine Mitchell, Mahon Jeff, Grover Steven A, Lewanczuk Richard, Leenen Frans, Tobe Sheldon, Lebel Marcel, Stone James, Schiffrin Ernesto L, Rabkin Simon W, Ogilvie Richard I, Larochelle Pierre, Jones Charlotte, Honos George, Fodor George, Burgess Ellen, Hamet Pavel, Herman Robert, Irvine Jane, Culleton Bruce, Wright James M
University of Alberta Hospital, Edmonton, Canada.
Can J Cardiol. 2002 Jun;18(6):625-41.
To provide updated, evidence-based recommendations for the therapy of hypertension in adults.
For patients with hypertension, a number of antihypertensive agents may control blood pressure. Randomized trials evaluating first-line therapy with thiazides, beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, alpha-blockers, centrally acting agents or angiotensin II receptor antagonists were reviewed.
The health outcomes that were considered were changes in blood pressure, cardiovascular morbidity, and cardiovascular and/or all-cause mortality rates. Economic outcomes were not considered due to insufficient evidence.
MEDLINE was searched for the period March 1999 to October 2001 to identify studies not included in the 2000 revision of the Canadian Recommendations for the Management of Hypertension. Reference lists were scanned, experts were polled, and the personal files of the subgroup members and authors were used to identify other published studies. All relevant articles were reviewed and appraised, using prespecified levels of evidence, by content experts and methodological experts.
A high value was placed on the avoidance of cardiovascular morbidity and mortality.
BENEFITS, HARMS AND COSTS: Various antihypertensive agents reduce the blood pressure of patients with sustained hypertension. In certain settings, and for specific classes of drugs, blood-pressure lowering has been associated with reduced cardiovascular morbidity and/or mortality.
The present document contains detailed recommendations pertaining to treatment thresholds, target blood pressures, and choice of agents in various settings in patients with hypertension. The main changes from the 2000 Recommendations are the addition of a section on the treatment of hypertension in patients with diabetes mellitus, the amalgamation of the previous sections on treatment of hypertension in the young and old into one section, increased emphasis on the role of combination therapies over repeated trials of single agents and expansion of the section on the treatment of hypertension after stroke. Implicit in the recommendations for therapy is the principle that treatment for an individual patient should take into consideration global cardiovascular risk, the presence and/or absence of target organ damage, and comorbidities.
All recommendations were graded according to strength of the evidence and voted on by the Canadian Hypertension Recommendations Working Group. Individuals with potential conflicts of interest relative to any specific recommendation were excluded from voting on that recommendation. Only those recommendations achieving high levels of consensus are reported here. These guidelines will continue to be updated annually.
为成人高血压治疗提供最新的、基于证据的建议。
对于高血压患者,多种抗高血压药物可控制血压。回顾了评估噻嗪类、β-肾上腺素能拮抗剂、血管紧张素转换酶抑制剂、钙通道阻滞剂、α-阻滞剂、中枢作用药物或血管紧张素II受体拮抗剂一线治疗的随机试验。
所考虑的健康结果包括血压变化、心血管发病率以及心血管和/或全因死亡率。由于证据不足,未考虑经济结果。
检索了1999年3月至2001年10月期间的MEDLINE,以识别未纳入2000年《加拿大高血压管理建议》修订版的研究。扫描参考文献列表,向专家咨询,并利用小组成员和作者的个人档案来识别其他已发表的研究。所有相关文章均由内容专家和方法学专家根据预先设定的证据水平进行审查和评估。
高度重视避免心血管发病和死亡。
益处、危害和成本:各种抗高血压药物可降低持续性高血压患者的血压。在某些情况下,对于特定类别的药物,血压降低与心血管发病率和/或死亡率降低相关。
本文件包含有关高血压患者在各种情况下的治疗阈值、目标血压和药物选择的详细建议。与2000年建议的主要变化包括增加了关于糖尿病患者高血压治疗的章节,将先前关于年轻人和老年人高血压治疗的章节合并为一个章节,更加重视联合治疗的作用而非单药重复试验,以及扩大了中风后高血压治疗的章节。治疗建议中隐含的原则是,个体患者的治疗应考虑整体心血管风险、靶器官损害的存在与否以及合并症。
所有建议均根据证据强度分级,并由加拿大高血压建议工作组投票表决。与任何特定建议存在潜在利益冲突的个人被排除在该建议的投票之外。此处仅报告达成高度共识的建议。这些指南将继续每年更新。